Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001439 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 255
- Enrollment target
NCT00001439: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00001439 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 255 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (325% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001439, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 255 participants
- Enrollment target
Study Summary
This is a phase I study of melanoma tumor antigen peptide vaccines. The nine amino acid peptides representing HLA-A2 restricted T cell epitope of the melanoma antigen, gp100 will be administered to patients emulsified in Incomplete Freund's Adjuvant, (IFA). The study is designed to evaluate the toxicity, immunologic effects and potential therapeutic role of repeated doses of gp100 peptide vaccines administered subcutaneously. Immune reactivity to the gp100 epitope peptides will be monitored in all patients by analysis of melanoma-specific T cell precursor frequency prior to and after immunization.
Interventions
- BIOLOGICAL gp100 human melanoma peptide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 1995-06 |
| Est. Completion | 2000-04 |
| Phase | Phase 1 |
What the finished NCT00001439 record still lists
NCT00001439 is an interventional study that assigns participants to a tested intervention. The registered 255 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (325% higher).
The record links to 0 conditions, and to 1 intervention - of which gp100 human melanoma peptide is the first listed.
NCT00001439 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00001439 about?
NCT00001439 is a clinical study titled "A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant". This is a phase I study of melanoma tumor antigen peptide vaccines. The nine amino acid peptides representing HLA-A2 restricted T cell epitope of the melanoma antigen, gp100 will be administered to patients emulsified in Incomplete Freund's Adjuvant, (IFA). The study is designed to evaluate the toxi...
What is the current status of trial NCT00001439?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 255 participants. The study started on 1995-06. Estimated completion is 2000-04.
What interventions are being tested in trial NCT00001439?
The interventions under investigation include: gp100 human melanoma peptide (BIOLOGICAL).
Who is sponsoring clinical trial NCT00001439?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00001439's enrollment target sits among peer trials
255 168th of 2000 higher than 1,833 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04623424 · 255 participants
Intestinal Microbiota in Stem Cell Transplant Transplant Admission
- NCT05114798 · 255 participants · NA
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
- NCT05336188 · 255 participants · Phase 2
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
- NCT05486637 · 255 participants · Early Phase 1
Vocal Emotion Communication With Cochlear Implants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia